- Home
- SUPN
as of 12-30-2025 3:51pm EST
$49.74
$1.52
-2.96%
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 2.6B | IPO Year: | 2012 |
| Target Price: | $61.60 | AVG Volume (30 days): | 634.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.16 - $57.65 | Next Earning Date: | 11-04-2025 |
| Revenue: | $681,539,000 | Revenue Growth: | 4.54% |
| Revenue Growth (this year): | 8.32% | Revenue Growth (next year): | 23.36% |
AI-Powered SUPN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 80.13%
80.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
Mottola Frank
Sell
SVP, Chief Tech. Ops. Officer
SUPN Dec 19, 2025
Avg Cost/Share
$50.35
Shares
20,000
Total Value
$1,008,150.00
Owned After
15,496
Bhatt Padmanabh P.
Sell
Sr. VP of IP, CSO
SUPN Dec 18, 2025
Avg Cost/Share
$44.44
Shares
710
Total Value
$31,552.40
Owned After
14,508
SEC Form 4
Khattar Jack A.
Sell
President, CEO
SUPN Oct 9, 2025
Avg Cost/Share
$51.00
Shares
59,900
Total Value
$3,029,336.39
Owned After
1,208,107
NEWHALL CHARLES W III
Sell
Director
SUPN Oct 9, 2025
Avg Cost/Share
$51.14
Shares
25,000
Total Value
$1,269,234.00
Owned After
104,644
Khattar Jack A.
Sell
President, CEO
SUPN Oct 2, 2025
Avg Cost/Share
$48.06
Shares
1,904
Total Value
$91,506.24
Owned After
1,208,107
SEC Form 4
Khattar Jack A.
Sell
President, CEO
SUPN Oct 1, 2025
Avg Cost/Share
$48.07
Shares
40,173
Total Value
$1,931,116.11
Owned After
1,208,107
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mottola Frank | SUPN | SVP, Chief Tech. Ops. Officer | Dec 19, 2025 | Sell | $50.35 | 20,000 | $1,008,150.00 | 15,496 | |
| Bhatt Padmanabh P. | SUPN | Sr. VP of IP, CSO | Dec 18, 2025 | Sell | $44.44 | 710 | $31,552.40 | 14,508 | |
| Khattar Jack A. | SUPN | President, CEO | Oct 9, 2025 | Sell | $51.00 | 59,900 | $3,029,336.39 | 1,208,107 | |
| NEWHALL CHARLES W III | SUPN | Director | Oct 9, 2025 | Sell | $51.14 | 25,000 | $1,269,234.00 | 104,644 | |
| Khattar Jack A. | SUPN | President, CEO | Oct 2, 2025 | Sell | $48.06 | 1,904 | $91,506.24 | 1,208,107 | |
| Khattar Jack A. | SUPN | President, CEO | Oct 1, 2025 | Sell | $48.07 | 40,173 | $1,931,116.11 | 1,208,107 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
Compare SUPN vs Leading Stocks
See how SUPN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.